2023
Cost‐effectiveness of prophylactic emicizumab versus prophylactic recombinant factor VIII in patients with moderate or mild hemophilia A without inhibitors in the United States
Potnis K, Viswanathan G, Bona R, Ito S, Kempton C, Pandya A, Krumholz H, Goshua G. Cost‐effectiveness of prophylactic emicizumab versus prophylactic recombinant factor VIII in patients with moderate or mild hemophilia A without inhibitors in the United States. American Journal Of Hematology 2023, 98: e247-e250. PMID: 37401660, DOI: 10.1002/ajh.27014.Peer-Reviewed Original ResearchAdultAntibodies, BispecificCost-Benefit AnalysisFactor VIIIHemophilia AHemorrhageHumansUnited States
2018
Clinical Outcomes of Plavix and Generic Clopidogrel for Patients Hospitalized With an Acute Coronary Syndrome
Ko DT, Krumholz HM, Tu JV, Austin PC, Stukel TA, Koh M, Chong A, de Melo JF, Jackevicius CA. Clinical Outcomes of Plavix and Generic Clopidogrel for Patients Hospitalized With an Acute Coronary Syndrome. Circulation Cardiovascular Quality And Outcomes 2018, 11: e004194. PMID: 29535091, DOI: 10.1161/circoutcomes.117.004194.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAgedAged, 80 and overClopidogrelCost SavingsCost-Benefit AnalysisDatabases, FactualDrug CostsDrug SubstitutionDrugs, GenericFemaleHemorrhageHumansMaleOntarioPatient AdmissionPatient ReadmissionPlatelet Aggregation InhibitorsPurinergic P2Y Receptor AntagonistsRecurrenceRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeConceptsAcute coronary syndromeGeneric clopidogrelClinical outcomesCoronary syndromePrimary outcomeRecurrent acute coronary syndromeSubstantial healthcare cost savingsPopulation-based observational studyPropensity-weighted cohortsComposite of deathTransient ischemic attackComposite end pointEffect of clopidogrelElevation myocardial infarctionHealthcare cost savingsCox proportional hazardsRate of deathIschemic attackACS hospitalizationCause readmissionBaseline characteristicsHospital dischargeRecurrent hospitalizationsMean ageMyocardial infarction
2017
Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers: Insights Derived From the FOURIER Trial
Arrieta A, Hong JC, Khera R, Virani SS, Krumholz HM, Nasir K. Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers: Insights Derived From the FOURIER Trial. JAMA Cardiology 2017, 2: 1369-1374. PMID: 29049467, PMCID: PMC5814995, DOI: 10.1001/jamacardio.2017.3655.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnticholesteremic AgentsCardiovascular DiseasesCholesterol, LDLCost-Benefit AnalysisDecision Support TechniquesDrug Therapy, CombinationFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypercholesterolemiaInsuranceInsurance, HealthInsurance, Health, ReimbursementMaleMarkov ChainsMiddle AgedMyocardial InfarctionPCSK9 InhibitorsQuality-Adjusted Life YearsStrokeUnited StatesConceptsQuality-adjusted life yearsIncremental cost-effectiveness ratioCost-effectiveness ratioProprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitorsCurrent pricesLife yearsPrivate payersAdditional quality-adjusted life yearPreliminary cost-effectiveness analysisCost-effectiveness standardsProbabilistic sensitivity analysesCost-effectiveness analysisPrivate payer perspectiveCost-effectiveness assessmentNegative returnsHealth system perspectiveSignificant discountUS dollarsDrug pricesPatent protectionPricesStatin treatment strategiesHealth insuranceTime horizonSubtilisin/kexin type 9 inhibitorsHow well does early-career investigators' cardiovascular outcomes research training align with funded outcomes research?
Crowley MJ, Al-Khatib SM, Wang TY, Khazanie P, Kressin NR, Krumholz HM, Kiefe CI, Wells BL, O'Brien SM, Peterson ED, Sanders GD. How well does early-career investigators' cardiovascular outcomes research training align with funded outcomes research? American Heart Journal 2017, 196: 163-169. PMID: 29421009, DOI: 10.1016/j.ahj.2017.09.008.Peer-Reviewed Original ResearchConceptsOutcomes researchEarly career investigatorsCardiovascular Outcomes ResearchFunded grantsCost-effectiveness researchBlood InstituteNational HeartClinical epidemiologySystematic reviewPrior trainingCommunity-engaged researchResearch training programsDissemination researchInvestigator trainingCompetency areasObservational researchCore competency areasInvestigators' interestOutcomes researchersInvestigatorsTraining programHealth informaticsSimilar resultsLungEpidemiologyImplications of Coronary Artery Calcium Testing for Treatment Decisions Among Statin Candidates According to the ACC/AHA Cholesterol Management Guidelines A Cost-Effectiveness Analysis
Hong JC, Blankstein R, Shaw LJ, Padula WV, Arrieta A, Fialkow JA, Blumenthal RS, Blaha MJ, Krumholz HM, Nasir K. Implications of Coronary Artery Calcium Testing for Treatment Decisions Among Statin Candidates According to the ACC/AHA Cholesterol Management Guidelines A Cost-Effectiveness Analysis. JACC Cardiovascular Imaging 2017, 10: 938-952. PMID: 28797417, DOI: 10.1016/j.jcmg.2017.04.014.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAmerican Heart AssociationBayes TheoremClinical Decision-MakingComputer SimulationCoronary AngiographyCoronary Artery DiseaseCoronary VesselsCost-Benefit AnalysisDecision Support TechniquesDrug CostsFemaleGuideline AdherenceHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleMiddle AgedModels, EconomicMonte Carlo MethodMultivariate AnalysisPractice Guidelines as TopicPredictive Value of TestsQuality of LifeQuality-Adjusted Life YearsTime FactorsTreatment OutcomeUnited StatesVascular CalcificationConceptsCoronary artery calciumQuality-adjusted life yearsStatin therapyArtery calciumLong-term statin therapyAtherosclerotic cardiovascular disease eventsCholesterol management guidelinesIncremental cost-effectiveness ratioCardiovascular disease eventsAtherosclerotic cardiovascular diseaseCost-effectiveness ratioCost-effectiveness analysisStatin candidatesCholesterol managementCardiovascular diseaseTreatment decisionsAmerican CollegeDisease eventsLifetime horizonLife yearsAmerican HeartSocietal perspectiveManagement guidelinesStatinsPatientsPriorities for Cardiovascular Outcomes Research
Khazanie P, Krumholz HM, Kiefe CI, Kressin NR, Wells B, Wang TY, Peterson ED. Priorities for Cardiovascular Outcomes Research. Circulation Cardiovascular Quality And Outcomes 2017, 10: e001967. PMID: 28710296, PMCID: PMC7811766, DOI: 10.1161/circoutcomes.115.001967.Peer-Reviewed Original ResearchCardiologyCost-Benefit AnalysisDelivery of Health CareHealth Care CostsHealth Services ResearchHumansInterdisciplinary CommunicationNational Heart, Lung, and Blood Institute (U.S.)Organizational ObjectivesOutcome Assessment, Health CarePatient-Centered CarePublic-Private Sector PartnershipsStakeholder ParticipationTranslational Research, BiomedicalUnited States
2016
Championing Effectiveness Before Cost-Effectiveness∗
Dhruva SS, Krumholz HM. Championing Effectiveness Before Cost-Effectiveness∗. JACC Heart Failure 2016, 4: 376-379. PMID: 27039130, PMCID: PMC5459398, DOI: 10.1016/j.jchf.2016.02.001.Peer-Reviewed Original Research
2015
The End of Journals
Krumholz HM. The End of Journals. Circulation Cardiovascular Quality And Outcomes 2015, 8: 533-534. PMID: 26555127, PMCID: PMC5322965, DOI: 10.1161/circoutcomes.115.002415.Peer-Reviewed Original Research
2013
How Do We Know the Value of Our Research?
Krumholz HM. How Do We Know the Value of Our Research? Circulation Cardiovascular Quality And Outcomes 2013, 6: 371-372. PMID: 23838103, PMCID: PMC5459392, DOI: 10.1161/circoutcomes.113.000423.Peer-Reviewed Original Research
2010
Focusing on Outcomes in Circulation: Cardiovascular Quality and Outcomes
Krumholz HM. Focusing on Outcomes in Circulation: Cardiovascular Quality and Outcomes. Circulation Cardiovascular Quality And Outcomes 2010, 3: 332-334. PMID: 20647573, DOI: 10.1161/circoutcomes.110.958017.Peer-Reviewed Original ResearchBeyond insurance coverage: Usual source of care in the treatment of hypertension and hypercholesterolemia. Data from the 2003-2006 National Health and Nutrition Examination Survey
Spatz ES, Ross JS, Desai MM, Canavan ME, Krumholz HM. Beyond insurance coverage: Usual source of care in the treatment of hypertension and hypercholesterolemia. Data from the 2003-2006 National Health and Nutrition Examination Survey. American Heart Journal 2010, 160: 115-121. PMID: 20598981, PMCID: PMC3025407, DOI: 10.1016/j.ahj.2010.04.013.Peer-Reviewed Original ResearchConceptsTreatment of hypertensionNutrition Examination SurveyInsurance statusMedication treatmentExamination SurveyNational HealthUsual sourceAdult Treatment Panel III recommendationsJoint National Committee 7Multivariable logistic regression modelingInsurance coverageSeparate multivariable modelsChronic disease managementLogistic regression modelingHigh-quality careRace/ethnicityCardiovascular diseaseMultivariable modelStratified analysisHypertensionHypercholesterolemiaRegular sourceCareDisease managementIndependent effects
2006
How useful is computed tomography for screening for coronary artery disease? Screening for coronary artery disease with electron-beam computed tomography is not useful.
Chen J, Krumholz HM. How useful is computed tomography for screening for coronary artery disease? Screening for coronary artery disease with electron-beam computed tomography is not useful. Circulation 2006, 113: 125-46; discussion 125-46. PMID: 16400723.Peer-Reviewed Original Research
2005
A Randomized Outpatient Trial of a Decision-Support Information Technology Tool
Apkon M, Mattera JA, Lin Z, Herrin J, Bradley EH, Carbone M, Holmboe ES, Gross CP, Selter JG, Rich AS, Krumholz HM. A Randomized Outpatient Trial of a Decision-Support Information Technology Tool. JAMA Internal Medicine 2005, 165: 2388-2394. PMID: 16287768, DOI: 10.1001/archinte.165.20.2388.Peer-Reviewed Original ResearchMeSH KeywordsAdultAmbulatory CareAttitude of Health PersonnelCost-Benefit AnalysisDecision Support Systems, ClinicalFemaleFloridaHealth ResourcesHospitals, MilitaryHumansKentuckyMaleMass ScreeningMultivariate AnalysisOutcome and Process Assessment, Health CarePatient SatisfactionPreventive MedicineQuality of Health CareConceptsProvider satisfactionAmbulatory clinic visitsUsual care patientsDays of enrollmentQuality process measuresQuality of careProportion of opportunitiesUsual careClinic visitsOutpatient trialSecondary outcomesPrimary outcomeAcute carePatient satisfactionIntervention groupHealth care opportunitiesPatientsClinical decisionCare opportunitiesPharmacy resourcesPreventive measuresProcess measuresCareMedical resourcesModest improvementThe Year in Epidemiology, Health Services, and Outcomes Research
Krumholz HM. The Year in Epidemiology, Health Services, and Outcomes Research. Journal Of The American College Of Cardiology 2005, 46: 1362-1370. PMID: 16198857, DOI: 10.1016/j.jacc.2005.06.060.Peer-Reviewed Original ResearchReport of the National Heart, Lung, and Blood Institute Working Group on Outcomes Research in Cardiovascular Disease
Krumholz HM, Peterson ED, Ayanian JZ, Chin MH, DeBusk RF, Goldman L, Kiefe CI, Powe NR, Rumsfeld JS, Spertus JA, Weintraub WS. Report of the National Heart, Lung, and Blood Institute Working Group on Outcomes Research in Cardiovascular Disease. Circulation 2005, 111: 3158-3166. PMID: 15956152, DOI: 10.1161/circulationaha.105.536102.Peer-Reviewed Original ResearchConceptsCardiovascular diseaseNational HeartOutcomes researchBlood Institute Working GroupReal-world effectivenessNational surveillance projectPatient-centered careClinical decision makingWorking GroupBlood InstitutePatient outcomesClinical practiceSurveillance projectCost of interventionHealthcare deliveryLungDiseaseCareCV conditionsResearch investigatorsGroupBasic scienceResearch prioritiesHeart
2002
The Cost-Effectiveness of Treatment for Varicocele Related Infertility
PENSON DF, PALTIEL AD, KRUMHOLZ HM, PALTER S. The Cost-Effectiveness of Treatment for Varicocele Related Infertility. Journal Of Urology 2002, 168: 2490-2494. PMID: 12441947, DOI: 10.1016/s0022-5347(05)64175-4.Peer-Reviewed Original ResearchConceptsImmediate IVFHealth care payorsRelated infertilityIntrauterine inseminationTreatment strategiesLive deliveryMain outcome measuresNumber of newbornsAdditional birthsCost-effectiveness analysisInfertile patientsImproved outcomesOutcome measuresPatient's perspectiveSurgical varicocelectomyIVFIncremental costInfertilityPatientsTreatmentPreferred approachBirthPayorsDeliveryVaricocelectomyTask Force #2—the cost of prevention: can we afford it? Can we afford not to do it?
Krumholz HM, Weintraub WS, Bradford WD, Heidenreich PA, Mark DB, Paltiel AD. Task Force #2—the cost of prevention: can we afford it? Can we afford not to do it? Journal Of The American College Of Cardiology 2002, 40: 603-615. PMID: 12204490, DOI: 10.1016/s0735-1097(02)02083-1.Peer-Reviewed Original Research
1999
Economics, health-related quality of life, and cost-effectiveness methods for the TACTICS (Treat Angina with Aggrastat® [tirofiban] and Determine Cost of Therapy with Invasive or Conservative Strategy)–TIMI 18 trial
Weintraub W, Culler S, Kosinski A, Becker E, Mahoney E, Burnette J, Spertus J, Feeny D, Cohen D, Krumholz H, Ellis S, Demopoulos L, Robertson D, Boccuzzi S, Barr E, Cannon C. Economics, health-related quality of life, and cost-effectiveness methods for the TACTICS (Treat Angina with Aggrastat® [tirofiban] and Determine Cost of Therapy with Invasive or Conservative Strategy)–TIMI 18 trial. The American Journal Of Cardiology 1999, 83: 317-322. PMID: 10072215, DOI: 10.1016/s0002-9149(98)00860-1.Peer-Reviewed Original ResearchConceptsQuality-adjusted life yearsHealth Utilities IndexLife yearsHealth-related qualityCost-effectiveness methodsNon-Q-wave myocardial infarctionUtility indexCost-effectiveness analysisDetermine CostImpact of invasiveEconomic formsUB92 formulationHealth care costsUnstable anginaRelative value scaleMedicare conversion factorMyocardial infarctionMedicare fee scheduleDepartmental costsEconomicsExpensive formFee scheduleTACTICS-TIMI 18Care costsOutcomes of patients
1995
A cost-effectiveness model of thrombolytic therapy for acute myocardial infarction
Kalish S, Gurwitz J, Krumholz H, Avorn J. A cost-effectiveness model of thrombolytic therapy for acute myocardial infarction. Journal Of General Internal Medicine 1995, 10: 321-330. PMID: 7562123, DOI: 10.1007/bf02599951.Peer-Reviewed Original ResearchConceptsQuality-adjusted life yearsTissue plasminogen activatorAcute myocardial infarctionAdditional quality-adjusted life yearMyocardial infarctionGUSTO trialThrombolytic therapyOne-year mortality dataOccluded Coronary Arteries (GUSTO-I) trialMortality dataPlasminogen activatorLong-term medical costsCoronary Arteries trialOne-year mortalityUse of streptokinaseInferior wall infarctionCost-effective therapyCost-effectiveness modelDecision analysis modelSurvival benefitSymptom onsetClinical outcomesRelative survival advantageThrombolytic agentsSurvival advantage
1993
Cost-effectiveness of a smoking cessation program after myocardial infarction
Krumholz H, Cohen B, Tsevat J, Pasternak R, Weinstein M. Cost-effectiveness of a smoking cessation program after myocardial infarction. Journal Of The American College Of Cardiology 1993, 22: 1697-1702. PMID: 8227841, DOI: 10.1016/0735-1097(93)90598-u.Peer-Reviewed Original ResearchConceptsSmoking cessation programAcute myocardial infarctionNurse-managed smoking cessation programCessation programsMyocardial infarctionYears of lifeBeta-adrenergic antagonist therapyLife expectancyOne-way sensitivity analysesTwo-way sensitivity analysesCost-effective interventionHealth care resourcesAntagonist therapySmoking ratesInfarctionCare resourcesSmokersInterventionProgram costsYearsExpectancyTherapyLife